Tonix launches Move Fibro Forward campaign to support millions living with Fibromyalgia

Tonix Pharmaceuticals Holdings CEO Dr Seth Lederman joined Steve Darling from Proactive to announce the launch of the “Move Fibro Forward” campaign by Tonix Medicines, Inc., the company’s commercial subsidiary. This initiative aims to raise awareness, offer support, and bring greater visibility to the millions of individuals affected by fibromyalgia—a chronic and often misunderstood pain disorder that has seen no new FDA-approved treatments in more than 15 years. Fibromyalgia impacts an estimated 10 million adults in the U.S., with approximately 80% of those affected being women. The condition is believed to result from amplified pain and sensory processing in the central nervous system, leading to widespread pain, non-restorative sleep and fatigue. Dr. Lederman emphasized that many people with fibromyalgia have endured their condition in silence, often without adequate recognition or treatment options. “We believe that acknowledging the reality of their experience, validating their suffering, and showing empathy is a vital step toward real progress,” he said. More information can be found at: www.movefibroforward.com. #proactiveinvestors #tonixpharmaceuticalsholdingcorp #nasdaq #tnxp #Biotech #MPOXVaccine #Smallpox #TNX801 #VaccineDevelopment #ClinicalTrials #PharmaceuticalNews #MedicalResearch #WHO #GlobalHealth #InfectiousDiseases #Biopharma #ProactiveInvestors”